SYM FINANCIAL Corp Purchases New Shares in Boston Scientific Corporation $BSX

SYM FINANCIAL Corp acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,881 shares of the medical equipment provider’s stock, valued at approximately $202,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. HM Payson & Co. raised its holdings in shares of Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after purchasing an additional 98 shares during the last quarter. Riverwater Partners LLC increased its position in shares of Boston Scientific by 3.3% during the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after acquiring an additional 98 shares during the last quarter. IVC Wealth Advisors LLC increased its position in shares of Boston Scientific by 4.9% during the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after acquiring an additional 102 shares during the last quarter. Park Square Financial Group LLC increased its position in shares of Boston Scientific by 5.2% during the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock valued at $208,000 after acquiring an additional 103 shares during the last quarter. Finally, HHM Wealth Advisors LLC increased its position in shares of Boston Scientific by 13.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after purchasing an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ellen M. Zane sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $102.24, for a total value of $296,598.24. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,467,460.16. The trade was a 10.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 180,204 shares of company stock valued at $18,544,846. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on BSX shares. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Robert W. Baird lifted their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $121.00 target price on shares of Boston Scientific in a report on Friday, October 17th. Canaccord Genuity Group restated a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Thursday, October 23rd. Finally, Morgan Stanley boosted their price objective on Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average target price of $123.77.

Boston Scientific Stock Down 1.4%

NYSE:BSX opened at $101.00 on Wednesday. The firm has a market cap of $149.66 billion, a P/E ratio of 54.01, a P/E/G ratio of 2.06 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The firm has a 50-day simple moving average of $101.07 and a two-hundred day simple moving average of $102.22.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.